RecruitingNot applicableNCT03954899

Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Natalie Denburg
Principal Investigator
Natalie Denburg, Ph.D.
University of Iowa
Intervention
melatonin(dietary_supplement)
Enrollment
230 target
Eligibility
56-85 years · All sexes
Timeline
2019 – 2025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03954899 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials